Teleflex Incorporated announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift System among the analyzed benign prostatic hyperplasia (BPH) treatment options. The data also show that the risk of surgical retreatment is similar between UroLift PUL, TURP and GreenLight PVP while highest following Rezum Water Vapor Therapy.
Purpose: To evaluate the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for extremely large prostates. Materials...
Objective: To elucidate potential biomarkers or mechanistic principles involved with the gut microbiota and its impact on prostate cancer pathogenesis.
Background: The standard of care (SOC) treatment (Tx) in the curative setting for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after 1st-line (1L) chemoimmunotherapy (CIT) is high-dose therapy with autologous stem cell rescue (HDT-ASCT) if responsive to 2L CIT; however, as many pts do not respond to or cannot tolerate 2L CIT, or are not intended for HDT-ASCT, outcomes remain poor.
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40% to 60% of patients.
Nymox Pharmaceutical has announced successful new study results from the long-term repeated injection group from the U.S. Phase III trials...
Purpose: Photodynamic therapy (PDT) is an emerging focal treatment modality for prostate cancer. However, the efficacy, safety, and functional outcomes of PDT are not clear. We performed a meta-analysis of available single-arm...
Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies.
A small Phase I trial of an MRI-guided focal laser ablation system, from Visualase, designed to treat the diseased portion...
Astellas Pharma Inc announced the European Commission (EC) has approved a label extension for Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy